Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 180Lymphoma 134Sarcoma 80Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Hodgkin Disease 50Lymphoma, Non-Hodgkin 49Leukemia 41Burkitt Lymphoma 40Lymphoma, Mantle-Cell 37Lymphoma, Follicular 34Neuroblastoma 30Ovarian Neoplasms 26Multiple Myeloma 26Neoplasms 24Lymphoma, Large-Cell, Anaplastic 23Carcinoma, Hepatocellular 23Neoplasm Metastasis 20Lymphoma, Large-Cell, Immunoblastic 19Triple Negative Breast Neoplasms 18HIV Infections 18Urinary Bladder Neoplasms 15Acquired Immunodeficiency Syndrome 15Osteosarcoma 14Liposarcoma 14Leiomyosarcoma 13Histiocytoma, Malignant Fibrous 13Breast Neoplasms, Male 13Lymphoma, B-Cell, Marginal Zone 12Inflammatory Breast Neoplasms 12

Interventions

Trabectedin 1Doxorubicin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Connective and Soft Tissue × Doxorubicin × Clear all
NCT00102609 2013-01-10

A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Completed
41 enrolled
Sarcoma

Neoplasms, Neoplasms by Histologic Type, Sarcoma, Neoplasms, Connective and Soft Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡